ArticleEuropean journal of nuclear medicine and molecular imaging2025

Lutetium-177 PSMA radioligand therapy in taxan-naive first- and second-line metastatic castration resistant prostate cancer after first-line ARPI therapy.

Mike Wenzel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.